Simple Summary Drug resistance is a long-standing impediment to effective systemic cancer
therapy and acquired drug resistance is a growing problem for new therapeutics that …

The antibody rilotumumab, which has been tested in multiple Phase 2 and Phase 3 trials,
has been reported to neutralize hepatocyte growth factor (HGF), the ligand for the oncogene …

Targeted therapies have opened new perspectives in clinical oncology. However, clinicians
have observed a lack of response in a relevant percentage of patients and frequent relapse …

Among hundreds of thousands of signal receptors contributing to oncogenic activation,
tumorigenesis, and metastasis, the hepatocyte growth factor (HGF) receptor–also called …

Targeted therapy is a hallmark of cancer treatment that has changed the landscape of
cancer management and enabled a personalized treatment approach. Nevertheless, the …

therapies was more pronounced than resistance to cytotoxic agents. The researchers then
went on to identify which factor or factors in particular were responsible for conferring …

Cancer therapeutics that target a signaling pathway to which the cancer cells are addicted
can deliver dramatic initial responses, but resistance is nearly always inevitable. A variety of …

Rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin G2
against hepatocyte growth factor (HGF) that blocks the binding of HGF to its receptor MET …

Cell-based drug screenings indicate that tumors displaying c-MET gene amplification are
“addicted” to MET signaling and therefore are very sensitive to MET-targeted agents …

The Reproducibility Project: Cancer Biology seeks to address growing concerns about
reproducibility in scientific research by conducting replications of 50 papers in the field of …